Resource Library

Discover helpful resources to
further understand DUPIXENT

Watch videos from providers,
patients, and caregivers, download materials and explore future events

Hear from other medical professionals who treat atopic dermatitis

DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Please view entire video for clinical trial efficacy and safety data and for full Important Safety Information.

INDICATION
DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATION:
DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Hi, I am Dr Neal Bhatia with the “Beyond the Surface” Series. We’ve had a bunch of patients who’ve done well with DUPIXENT therapy, but there was one who stood out most recently. I remember him well. He’s 59 years old, he’s skin type five and he just was absolutely covered in eczematous plaques and dryness and excoriation. You could tell he was really giving in to his disease and accepting where he was at. Even more so, just the sense of frustration that he has had nowhere to turn.

I remember the first day when he came in, he talked about his skin as a prison, the redness, the thickness of his skin. He felt like his skin was broken. My patient made it pretty clear to us that the itch that he was experiencing was by far the most overwhelming issue that he had had. His coworkers, they were distracted by his scratching, thinking that he had something contagious in terms of shaking hands or saying hello, which kept reminding him of his condition. After we had enough time to discuss the journey with him, there was very little doubt that DUPIXENT was the therapy that we needed to get into his hands. And we spent some time discussing with him about the safety profile. The most common adverse reactions with an incidence greater than or equal to 1% at Week 16 in clinical trials were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infections and dry eye.

When we saw the patient back after his loading dose and his second injection, we really started to see a significant improvement in the EASI score and the amount of body surface area that was covered in severe plaques. His description of itching and the urge to scratch was much more encouraging. He made it clear to us that being on DUPIXENT had changed the way he thought about his disease. He had described it as his enemy, as his jail. He felt like he had more control of his disease, more control of his itching as he was the one giving himself the shots. He felt like he was actually more involved in his treatment. And that gave him a sense of encouragement in terms of how he was going to break the itch scratch cycle himself.

INDICATION
DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-tosevere atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATION:
DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Hi, I’m Dr Autumn Burnette with the “Beyond the Surface” Series.

So I have a patient who’s in her late 30s. It’s a professional female. She has skin of color. I would describe the severity of this patient to be moderate-to-severe. She described the itch as being unbearable, and chronic, and throughout the day. And she even reported to me that she felt as if her skin was crawling. And my patient works in healthcare. So it was very concerning to her, not only cosmetically and the appearance of her skin being in the healthcare setting, but also the burden of having to frequently hand wash, which may even exacerbate her current moderate-to-severe condition. What I’ve observed in patients with skin of color is that it’s a more heterogeneous type of appearance of the lesions on the skin. She mentioned having lesions on her skin that were changing the actual pigment of her skin. And she even described to me that she didn’t even actually know the true pigment of her skin, because most of her skin was covered in atopic dermatitis lesions. She wanted my help and I actually had help to give her. I explained to her that DUPIXENT was an injectable monoclonal antibody that was a biological approach to managing her moderate-to-severe atopic dermatitis. When discussing the safety profile of DUPIXENT with my patients, I do explain to them that, of course, every patient responds to drugs differently. The most common adverse reactions, incidence greater than or equal to 1% at Week 16 in clinical trials, were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye.

At her first follow-up, which was approximately four weeks after we started DUPIXENT, the patient mentioned to me that her itch level was greatly diminished, which I was excited for. She was able to expose her hands and arms. She was actually getting compliments from people about the appearance of her skin. I’ve been very excited to continue along this journey with her, and she has been excited about continuing DUPIXENT therapy.

INDICATION
DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATION:
DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Hi, I’m TJ Chao with the “Beyond the Surface” Series.

So I have a 55-year-old patient who I’ve been seeing now for about 17 years, and he played in a cover band for a major rock group. He had, ah, moderate-to-severe atopic dermatitis that was affecting his body, his face, as well as his hands. So when my patient first came into the practice, he described his disease as unpredictable. He never knew when it was gonna cause a problem. And it really affected his ability to play his music and feel comfortable. My patient would say that their skin was very red. It was thick, and the more he rubbed his skin, the thicker it became. But his worst complaint were his hands. His hands would essentially peel, scale. When he’s trying to play in the band, his fingers will literally crack and bleed while he’s on stage. My patient described itching that he would have just about at every point during the day. He would get up and try to put lotion on his skin throughout the night in order to feel better. He realized that he’s got to make a big change in the way he’s been treating his disease. When I described DUPIXENT to my patient, the goal and hope was it was going to help his skin, not only in the short-term, but also in the long-term. We had been treating his disease for so long episodically. With my patient, we talked about the risks and safety profile of DUPIXENT. The most common adverse reactions, incidence greater than or equal to 1% at Week 16 in clinical trials, were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eyes.

When I prescribed DUPIXENT to my patient, within a few weeks, he sensed a difference in his body. But what was most dramatic was the improvement in his hands and especially his fingertips. His hands were slightly red, but not eczematous as they were before. He was less itchy. I think the most pivotal point was when he went on a trip and for the first time he was sweating, he was hot on stage, the lights were beaming down on him...he looked a lot more comfortable. He realized that DUPIXENT was treating him not only on the outside what he could see and feel, but it was also treating him on the inside. He realized that the disease was now under control. He has something that’s effective short- and long-term.

INDICATION
DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATION:
DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Hi, I’m Dr Jennifer Soung with the “Beyond the Surface” Series. Of the patients that I’ve treated, one particular patient comes to mind. He’s an eight-year-old boy who is Southeast Asian, and was referred to me by his pediatrician because of really stubborn disease. In skin of color, it can be harder to distinguish or make a diagnosis because it may not look so typical. The plaques can be more lichenified and thicker, and so may look like psoriasis. The appearance of the lesions are different, as well, in skin of color because the redness isn’t always so bright.

Mom described it as his skin was on fire. Even at times she said it was like an active volcano. It was always brewing; he never had clear skin. He wanted to hide his eczema. Kids at school started to notice and would ask what was going on. Really, that sense of lack of control over his skin, his itching. As soon as the FDA approved it, I remember that day, he was one of my first patients that I called. And the parents came right in. In this situation, the parents knew that they needed something more, and wanted to keep his inflammation and his atopic dermatitis controlled. When I prescribe DUPIXENT to my patient, I always share with them the most common adverse events. The most common adverse reactions, incidence of greater than or equal to 1% at Week 16 in clinical trials, were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex infections, and dry eye.

After starting DUPIXENT, on his first visit back to the office, I didn’t even need to ask him how he was doing because he just smiled at me. I knew that we were on the right path to healing his skin because he had described a relief in his itch. That was a big accomplishment. I’ve seen him improve over several weeks, and his skin healed really well. He was wearing short sleeves and shorts when he came to the office. He no longer felt like he had to cover all his skin. I remember mom and dad telling me it was like a huge weight that had been lifted off of them… because they saw that this medicine was actually helping relieve that itch and break that itch-scratch cycle. So the family, as well as the patient, have been thrilled. And even the little boy, my patient, says that the injection now is worth it.

INDICATION
DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATION:
DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Hi, I’m Dr Amy Spizuoco with the “Beyond the Surface” Series. This patient came into my office, 13-year-old female, who was fairly new to me.

She was very soft-spoken and very quiet. She didn’t really have much to say because she was just so self-conscious and so uncomfortable. Her mother was her main advocate and let me know, “We have to do something to help her.” She really had this uncontrollable itch. She couldn’t stop. She was really uncomfortable at home, at school amongst her classmates and teachers, just that unsuppressible itch. She had lesions on different parts of her body...that were extremely visible to her. And she just felt extremely uncomfortable in her skin. She had tried several different prescription steroid creams. So, we came to the conclusion that DUPIXENT is going to be the choice for her. The most common adverse reactions, incidence greater or equal to 1% at Week 16 in clinical trials, were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. I really like the fact that DUPIXENT is not an immunosuppressant or a steroid because it makes me feel that the medicine is a different way of treating atopic dermatitis. In order to get my patient and her mother more comfortable with using a medication that’s an injection, I explained to them that injection therapy is not a new treatment to our armamentarium or to any of our patients.

After my patient arrived to the office at Week 16, she came in smiling, sat down in the chair right away, was ready to move on with treatment. After initiating treatment with DUPIXENT, she stated that the visibility of her lesions were much reduced and the itch intensity of her lesions were significantly reduced. While my patient has been on DUPIXENT for quite a while now, she told me she feels so much more comfortable in her skin and she’s a cheerleader.

INDICATION
DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATION:
DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Hi, I’m Melodie Young with the “Beyond the Surface” Series. I think about this young man sort of just entering middle age, who has had very few days of his life that he was not battling atopic dermatitis.

When I asked this gentleman how this disease was affecting his life, his response was simple: It was his life. It’s how he spent all of his time, his energy. He told me that the itch was unrelenting. He talked about every decision that he made about what he was going to wear. Some friends were going over into East Texas camping, and he wanted to go, but he knew that they were probably going to want to swim. And he didn’t really want them to see his skin all over. I was hopeful that we had something that was going to be a major shift in his care. When you’re introducing DUPIXENT to a patient, what we have to do is to make sure that they also understand what the safety profile is. The most common adverse reactions, incidence of greater than or equal to 1% at Week 16 in clinical trials, were injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye.

He started his shots, and he came back to see me about 4 weeks later. And he said, this is amazing. He had on shorts. He became less itchy, more comfortable. And he wasn’t constantly thinking about his skin. His skin had healed in ways that he had never experienced. He said, “Look at this... before, I would never have let them see this much of my body, this much of my skin.” Now he was able to tell patients there is something that can help you.

Providers are paid consultants.

Hear from DUPIXENT patients

Growing up, my skin was flaking, my skin was itching. My skin was red. I would just scratch constantly, and the itching was something that I could never satisfy.

Over time, my itching got less and less. After starting treatment, I started noticing some changes with my skin. I noticed that the redness and irritation was reduced, and I noticed that the overall texture of my skin was smoother.

Today, I feel like I can manage my atopic dermatitis symptoms, and that is a huge relief! Of course, this is just my experience, and everyone’s experience with DUPIXENT will be different.

I like the outdoors. It’s always been a part of my life. Growing up, I was an athlete and played a lot of outdoor sports. But I live with severe atopic dermatitis, and sometimes the outdoors and my eczema do not go well together. At any time, the heat, the sun, the sweat, could lead to flare-ups.

It was hard when my friends would invite me to outdoor activities. I’d be thinking—okay, will my eczema flare up? What should I bring? How long should I stay outside? Should I even go? It was like a guessing game having to anticipate what my skin might do.

But now, DUPIXENT is helping me manage my eczema. I feel I have control over my symptoms. My skin is clearer and I have less itch. Of course, everyone’s experience with DUPIXENT is different.

Today, I am able to spend more time outdoors by worrying less about my skin. I still limit my time in the sun, but eczema is not my first thought when I go outside and that feels great.

ANNIE:

It was hard to not have a solution that worked for me. There was always something that I needed to do, always like a medicine I needed to take or a topical that I had to put on my skin.

SUE:

As a mom, I felt helpless, and we really felt out of control, and we needed to find something different that would work for her. Annie’s eczema specialist knew about DUPIXENT and thought that Annie was appropriate for it.

ANNIE:

Since starting DUPIXENT, my skin is a lot more clear. It’s a lot calmer.

SUE:

We did notice a difference within the first few weeks, and it has continually improved.

ANNIE:

My life doesn’t revolve around my skin anymore.

SUE:

Now, when she goes out and plays volleyball or hangs out with her friends, she can just be a kid, and that is a huge relief as a parent.

I started to get these red, scaly patches on my skin. These red patches would itch constantly. To me, the itching felt like there were tiny little bugs underneath my skin, and they were just constantly crawling.

After starting treatment with DUPIXENT, my open sores were able to heal, and my itching was going away. One day, I noticed I wasn’t constantly itching. I will never forget that time.

I noticed my skin was getting clearer and smoother. Today, I’m still on treatment with DUPIXENT. I cherish every moment that I’m not bothered by the atopic dermatitis symptoms. Of course, this is just my experience. Everybody is unique, so someone else’s experience with DUPIXENT will be different.

Actual patients treated with DUPIXENT. Individual results may vary.

Hear from caregivers of DUPIXENT pediatric patients

Dear DUPIXENT,

My teenage daughter, Ore, has been dealing with severe atopic dermatitis for a few years now. What started off as patches of dry skin here and there turned into constant itching. We tried many different treatments. They’d work for a short time, but then her symptoms would come back again. It was hard for her and our family to manage. We saw a few different doctors. Eventually we were referred to Ore’s current specialist. He was committed to helping Ore find relief and manage her symptoms. And that is how we started treatment with DUPIXENT.

We were a little skeptical at first. Then we noticed her skin clearing and improving over time. It was such a relief to find something that works for her. Today, Ore is able to manage her symptoms and we are all very relieved. Thank you, DUPIXENT, for what you’ve done for my daughter. Thank you for helping her manage her eczema.

Sincerely,

Yetunde

Dear DUPIXENT,

My teenage son, Max, had uncontrolled severe atopic dermatitis for years. The scabs on his arms were so embarrassing that he had to wear long sleeves under his school uniform, even in the 90-degree Florida summers. We tried many different treatments, but nothing seemed to adequately help him manage his symptoms. Then we talked to our dermatologist about DUPIXENT.

After being on treatment with DUPIXENT, Max began noticing clearer skin and less itching. And his skin has continued to improve over time. And what’s more, he’s comfortable wearing short-sleeved shirts. Thank you, DUPIXENT, for what you’ve done to help my son manage his eczema. We are eternally grateful.

Sincerely,

Ana

Caregivers to actual patients treated with DUPIXENT. Individual results may vary.

Download helpful resources about DUPIXENT for uncontrolled moderate-to-severe atopic dermatitis

ADULTS (AGED 18+ YEARS)
TREATED WITH DUPIXENT

SHAWN’S PROFILE RACHEL’S PROFILE

ADOLESCENTS (AGED 12-17 YEARS) TREATED WITH DUPIXENT

ANNIE’S PROFILE JASON’S PROFILE

CHILDREN (AGED 6-11 YEARS)
TREATED WITH DUPIXENT

HANNAH’S PROFILE RYAN'S PROFILE

DOSING INFORMATION
FOR DUPIXENT

DOWNLOAD AND SHARE

EFFICACY AND SAFETY
PROFILE FOR DUPIXENT

DOWNLOAD AND SHARE

Join us at virtual educational events for DUPIXENT in 2021

Explore Dupixent

Tour the DUPIXENT virtual booth to learn more about this novel therapy, including: identifying appropriate patients, MOA, efficacy and safety data, and how to get patients started.

VISIT BOOTH

Mark your calendars for these future events

Women’s Dermatologic
Society (WDS) Forum

October 8-10, 2021
Scottsdale, AZ

Fall Clinical Dermatology
Conference

October 21-24, 2021
Las Vegas, NV

American College of Allergy,
Asthma & Immunology
Annual Scientific Meeting

November 4-8, 2021
New Orleans, LA

LOAD MORE

American Academy of Allergy
Asthma & Immunology Annual Meeting

February 25-28, 2022
Phoenix, AZ

The Society of Pediatric Dermatoloy
(SPD) 47th Annual Meeting

July 7-10, 2022
Indianapolis, IN

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

Learn how we can help

WATCH INFORMATIONAL VIDEOS ABOUT:

ENROLLING IN DUPIXENT MyWay

HOW DUPIXENT IS DELIVERED

Important Safety
Information and Indication

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Atopic Dermatitis Patients with Comorbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Healthcare providers and patients may call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/ to enroll in or obtain information about the registry. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.

Indication

DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.